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1. Introduction  
Human diseases can be treated by the transfer of therapeutic genes (transgene) into specific 
cells or tissues of patients to correct or supplement defective, causative genes. Gene therapy 
offers a solution to controlled and specific delivery of genetic materials (DNA and RNA) to 
targeted cells. The success of gene therapy depends on the ability to deliver these 
therapeutic materials to targeted site. Viral vectors (e.g. adenovirus) are very effective in 
term of transfection efficiency, but they have limitations in vivo, particularly by their safety 
concern and non tissue-specific transfection. Non-viral gene transfer systems are limited by 
their lower gene transfer efficiency, low tissue specificity and transient gene expression. 
Chitosan is a polysaccharide usually obtained from deacetylation of chitin, which may be 
extracted from various sources, particularly from exoskeletons of arthropods such as 
crustaceans. The goal of this chapter is to introduce the readers to chitosan as a DNA/small 
interfering RNA (siRNA) delivery vector, as well as different variable strategies to improve 
cellular transfection and its potential clinical application. the first section is to present of 
chapter (section 1). The second section presents the discussion about barriers to 
DNA/siRNA delivery in vitro and in vivo. It is important to have a clear overview of 
obstacles to the in vivo treatment with DNA/siRNAs. Different in vivo administration routes 
will encounter different physiological barriers, and complications may be furthered by 
different cells in organs and tissues (section 2).  The third section provides the readers with 
an understanding of the key steps of cellular internalization of DNA/siRNA non-viral 
vectors. Internalization of non-viral vector-based DNA/siRNA delivery system into cells 
typically occurs through endocytosis (section 3). the fourth section describes chitosan as a 
vector for gene therapy (section 4) followed by chitosan structure and physicochemical 
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behaviour  (section 5), general strategies for chitosan modification (section 6), chitosan-DNA 
delivery system (section 7), chitosan-siRNA delivery system (section 8), and potential 
applications of chitosan–DNA/siRNA nanoparticles (section 9). Our current research will be 
summarized in the section of conclusion. 
2. Barriers to gene delivery using non-viral vectors  
2.1 Viral gene vectors 
Gene transfer can occur through 2 delivery systems: viral or non-viral vectors. Viral gene 
therapy consists of using viral vectors which, given their structure and mechanisms of 
action, are good candidates or models to carry therapeutic genes efficiently, leading to long-
term expression. Viruses are obvious first choices as gene transport. They have the natural 
ability to enter cells and express their own proteins. Nowadays, most viral vectors used are 
retroviruses, herpes virus, adenoviruses and lentiviruses. Unfortunately, certain viral 
vectors (for example, adenoviruses) can elicit a robust cellular immune response against 
viral and some transgenic proteins, so their use has been limited to studies in immune-
compromised animals (Seiler et al., 2007). Adeno-associated viruses (AAV), which have 
been considered safe, appear to be immunogenic in several experimental settings 
(Vandenberghe & Wilson, 2007) and in a clinical trial (Mingozzi & High, 2007). Some serious 
adverse events have occurred with viral gene therapy. One patient died of fatal systemic 
inflammatory response syndrome after adenoviral gene transfer in 1999 (Raper et al., 2003). 
Two children developed leukemia-like clonal lymphocyte proliferation after recombinant 
retroviral gene transfer in 2000 (Hacein-Bey-Abina et al., 2003), and 1 of them died after 
unsuccessful chemotherapy late in 2004. Attention focused recently on the tragic death of a 
young female patient in a gene therapy study (intra-articular injection of AAV vectors) of 
severe RA in 2007 (Kaiser, 2007).  
2.2 Non-viral gene vectors 
Non-viral gene transfer systems offer several potential advantages over virus vectors. They 
are non-infectious, relatively non-immunogenic, have low acute toxicity, can accommodate 
large DNA plasmids or RNA, and may be produced on a large scale (Castanotto & Rossi, 
2009; Gary et al., 2007).  Non-viral gene therapy has been explored by physical approaches 
(transfer by gene gun, electroporation, ultrasound-facilitated and hydrodynamic delivery) 
as well as chemical approaches (cationic lipid-mediated gene delivery and cationic polymer-
mediated gene transfer). Numerous chemical non-viral gene transfer systems have been 
proposed, including naked DNA, cationic liposomes, histones, and polymers (Gao et al., 
2007; Ulrich-Vinther, 2007). The main drawback of non-viral vectors as gene carriers is their 
typically low transfection efficiency (Gao et al., 2007; Giannoudis et al., 2006). Furthermore, 
the in vivo delivery of non-viral liposome/plasmid DNA complex triggers an immune 
response (Sakurai et al., 2008). Non-viral gene therapy with cationic liposomes has already 
been tested in clinical trials that dealt with the treatment of inherited genetic disorders (for 
example, cystic fibrosis) (Hyde et al., 2000) and cancer (Ramesh et al., 2001). Synthetic and 
natural cationic polymers (positively-charged) have been widely used to carry DNA or 
siRNA (both negatively-charged) and condense it into small particles, facilitating cellular 
internalization via endocytosis through charge-charge interactions with anionic sites on cell 
surfaces. Although existing non-viral vectors have been found to enable DNA expression 
after in vivo delivery, the efficiency and duration of ensuing gene expression have proven to 
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be unsatisfactory. Research efforts to improve the in vivo DNA-delivery efficacy of non-viral 
vectors are ongoing. 
2.3 Barriers to DNA delivery 
Systemic gene delivery involves a systemic approach in which exogenous genes are 
delivered to cells in a certain tissues, and secreted gene products are released into the 
circulatory system where they could modulate disease processes throughout the body. 
Systemic non-viral gene delivery has become an attractive alternative to viral vectors 
because of their safety, versatility and ease of preparation (Li & Huang, 2006). Genes can be 
delivered systemically (intramuscularly, intravenously, subcutaneously or, in animals, 
intraperitoneally). Otherwise, hydrodynamic-based gene delivery through systemic DNA 
injection offers a convenient, efficient and powerful means for high-level gene expression in 
animals (Liu & Knapp, 2001; Suda & Liu, 2007). This method is expected to be evaluated in 
patients soon (Romero et al., 2004). The limitations of the systemic approach to gene therapy 
are essentially the advantages of local delivery: exposure of non-target tissues to the 
therapeutic agent may have toxic effects or may compromise the immune system of the 
patient. Certain proteins will likely require very high levels of synthesis to achieve 
therapeutic function.  
Ideally, gene therapy must protect DNA against degradation by nucleases in intercellular 
matrices so that the availability of macromolecules is not affected. Transgenes should be 
brought across the plasma membrane and into the nucleus of targeted cells but should have 
no detrimental effects. Hence, interaction with blood components, vascular endothelial cells 
and uptake by the reticuloendothelial system must be avoided. For DNA-based gene 
therapy to succeed, small-sized systems must internalize into cells and pass to the nucleus. 
Also, flexible tropisms allow applicability to a range of disease targets. Last but not least, 
such systems should be able to escape endosome-lysosome processing for endocytosis.  
2.4 Barriers to siRNA delivery  
The discovery of small interfering RNAs (siRNAs) has given renewed vision to the 
treatment of incurable diseases and genetically-associated disorders. Short double stranded 
(ds) RNA of 21-23 bp was cleaved by the RNAse III-like protein Dicer and incorporated into 
RNA-induced silencing complexes (RISC) (Hammond et al., 2000). Chemically-synthesized 
siRNAs and short hairpin RNA (shRNA) expression plasmids, which are sequence-specific 
for mRNA targeting, are methods commonly employed to mimic Dicer cleavage (Chen et 
al., 2007). However, siRNAs are susceptible to nuclease destruction and cannot penetrate the 
cell membrane because of their highly-charged backbone. An effective delivery system 
would enclose siRNA in carriers for protection and transport to the cytoplasm of targeted 
cells but should have no detrimental effects such as specific and non-specific off-targeted 
effects. Off-target effects can be divided into two categories: specific and non-specific off-
targeted effects. Off-targeted effects may cause inflammation including interferon response, 
cell toxicity, and unintended gene knockdown. 
Turning siRNA into drugs is a 3-step process. The design and in vitro screening of target 
siRNAs are followed by incorporating stabilizing chemical modifications in lead siRNAs, as 
required, and end in the selection as well as in vivo evaluation of delivery technologies that 
are appropriate for the target cell type/organ and disease setting (Vaishnaw et al., 2010). 
After nearly 10 years of study and development, many problems have been resolved, such 
as improving the stability of siRNAs, and avoiding 2 types of off-target effects. A recent 
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anti-influenza study showed that the anti-viral activity of siRNA as found to be due to 
active siRNA. However, a different non-targeting control siRNA also had significant anti-
viral activity (Mook et al., 2007). siRNA targeting vascular endothelial growth factor for 
patients with age-related macular degeneration (AMD) are currently in clinical trial. But 
further study showed that the inhibition is a siRNA classic effect, which is sequence- and 
target-independent (Jackson & Linsley, 2010). The off-target effect can be minimized by 
optimizing the rules and algorithms for siRNA design (Vaishnaw et al., 2010). However, 
several other factors limit the utility of siRNAs as therapeutic agents, such as competition 
with endogenous RNA, induction of immune responses, degradation in lysosomes after 
endocytosis (Dominska & Dykxhoorn, 2010; Wang et al., 2010).  Unprotected, naked siRNAs 
are relatively unstable in blood and serum and have short half-lives in vivo  (Gao et al., 
2009). Naked siRNAs do not freely cross cellular membranes because of their large 
molecular weight (~13 kDa) and strong anionic charge. They are rapidly degraded by 
nuclease. Physiological barriers hinder siRNAs from reaching their targets, thereby reducing 
their therapeutic efficacy. Moreover, siRNA molecules have unfavorable physicochemical 
properties (negative charge, large molecular weight and instability). Therefore, they need 
delivery systems to overcome physiological obstacles and prolong vascular circulation by 
reducing renal clearance, protecting them from serum nucleases, improving their effective 
bio-distribution as well as targeted cellular uptake with endosomal escape and, finally, 
promoting trafficking to the cytoplasm and loading onto RISC. Therefore, delivery systems 
are required to facilitate siRNA access to intracellular sites of action.Barriers to siRNA 
delivery depend on the targeted organ and routes of administration. For example, 
intravenous (IV) administration is the most commonly used technique. The endothelial wall 
in the vasculature presents the primary delivery barrier to siRNAs. The endothelial barrier is 
often altered by inflammatory processes (e.g., RA, infection) (Moghimi et al., 2005). siRNAs 
leave a blood vessel to enter tissue. After reaching target cells, they undergo internalization 
via endocytosis, escape from endosomes, and release into the cytosol and, finally, load onto 
RISC. At the same time, siRNAs undergo elimination. The mononuclear phagocyte system is 
responsible for removing circulating foreign particles from the bloodstream by the 
phagocytosis of resident macrophages (Moghimi et al., 2005).  
3. Cellular internalization of non-viral vector delivery system 
There are seven steps should be overcome before the expression of exogenous DNA. They 
are (1) complexation, (2) in vivo administration, (3) endocytosis, (4) escape from 
endolysosome, (5) release of DNA, (6) trafficking through cytoplasm and (7) finally import 
of DNA into nucleus. (If siRNA is used as exogenous nucleotide, the last two steps can be 
ignored; but if vector-expressed siRNA is used, the process remains the same.) During each 
step, many factors may come into play, inducing toxicity, immunogenicity or affecting 
transfection efficiency. (1) During complexation, the non-viral vectors-DNA interaction is 
driven mainly by the electrostatic interaction between the polycation and the charged 
phosphate groups leading to reversible linear to globule transition of DNA. The ability of 
the non-viral vectors to condense DNA into nanoparticles is often critical for transfection 
efficiency since DNA must be protected from DNase degradation. (2) Different in vivo 
administration routes will meet different physiological barriers. Therefore, it is suggested 
that the corresponding primary cells and similar physiological barriers should be tested in 
vitro as far as possible, before in vivo administration is attempted. (3) The following step is to 
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reach its target, the cell by endocytosis. In this respect it is well accepted that the 
polyelectrolyte complex polycation-DNA exhibiting a net positive charge binds to 
negatively charged cell membrane. (4) After the internalization the following crucial step in 
gene delivery with cationic polymers is the escape of the polymer/DNA complexes from the 
endosome. (5) The inefficient release of the DNA/polymer complex from endocytic vesicles 
into the cytoplasm is indicated as one of the primary causes of poor gene delivery. (6) and 
(7) the following step, the nuclear envelope is the ultimate obstacle to the nuclear entry of 
plasmid DNA. This obstacle is also considered crucial and two main mechanisms were 
proposed to explain how plasmid DNA enters into the nucleus: (i) a passive DNA entry into 
the nucleus during cell division when the nuclear membrane is temporarily disintegrated or 
(ii) an active transport of the DNA through the nuclear pores. 
4. Chitosan as a vector for gene therapy 
Cationic polymers, such as chitosan, are promising candidates for DNA transport in non-
viral delivery systems (Kean & Thanou, 2010; Tong et al., 2009). Chitosan, a 
linear polysaccharide composed of randomly distributed ǃ-(1-4)-linked D-glucosamine 
(deacetylated unit) and N-acetyl-D-glucosamine (acetylated unit), and has once been 
considered as an attractive gene transfer candidate for its superior biocompatibility, 
superior biodegradability and low cell toxicity. In recent years, with more researching 
methods involved, a more accurate and subtle view on the process of the entry of 
chitosan/DNA complexes into the cell nucleus has been developed. The enabling 
characteristics of Chitosan-DNA nanoparticles include biocompatibility, multiple ligand 
affinity, and a capacity of taking up large DNA fragments, while remaining small in size 
(Techaarpornkul et al., 2010). Chitosan and its derivatives, as favorable non-viral vectors 
involved in plasmid DNA delivery, have attracted attention in the field of siRNA delivery in 
vitro and in vivo (Andersen et al., 2009; Howard et al., 2009). Chitosan was once believed to 
be less effective than most other non-viral vectors because of its low stability and buffering 
capacity. However, recent technological advances in the chemical modification of chitosan 
have instituted improvements of its transfection efficiency without disturbing its 
biocompatibility and biodegradability. It has been demonstrated that transfection level is 
closely related to the molecular weight of polymers (Godbey et al., 1999). Chitosan (10-150 
kDa), with a specific degree of deacetylation, allows maximum transgenic expression in vitro 
(Lavertu et al., 2006). Another strategy for improving transfection is to take advantage of the 
mechanism of ligand-mediated uptake by cells to promote targeting and internalization, 
enhancing transfection efficiency. Ligand-mediated transfection has been shown to facilitate 
DNA internalization into cells via membrane receptors both in vitro and in vivo. Cell-specific 
ligand modification such as galactose, transferrin, folate and mannose can also effectively 
enhance the specificity of transfection through receptor-mediated endocytosis. Galactose 
ligand modification has been used to target HepG2 cells through the interaction with 
asialoglycoprotein receptors (ASGP-R) (Gao et al., 2003). A transferrin receptor is found on 
many mammalian cells, therefore it can be used as a universal ligand (Dautry-Varsat, 1986). 
Folate is not only over-expressed on macrophage surfaces, but is also over-expressed on 
many human cancer cell surfaces (Lee et al., 2006). Antigen presenting cells (APCs), the ideal 
targets of DNA vaccine, such as macrophages and immature dendritic cells are the target 
cells of mannose ligand (Kim et al., 2006). The specificity of these modifications can be 
demonstrated through ligand competitive inhibition experiments. 
www.intechopen.com
 
Non-Viral Gene Therapy 
 
 
460 
The low stability, low buffering capacity and low cell-specificity have also hindered its 
clinical applications. However, as a nature resource-based polysaccharide, chitosan has 
more functional groups that can be chemically modified than other cationic polymers, thus 
has many more potential chemical derivatives to overcome the deficiencies. Chitosan has 
been experimentally modified using hydrophilic, hydrophobic, pH-sensitive, 
thermosensitive and cell-specific ligand groups for enhancement of transfection efficiency 
(Ishii et al., 2001). The degree of deacetylation (DDA) and the molecular weight (MW) of 
chitosan or its derivatives, can affect the ultimate transfection efficiency. Most 
chitosan/DNA complexes are highly deacetylated (above 80%), because chitosan with a 
high degree of deacetylation exhibits an increased DNA binding efficacy (Kiang et al., 2004). 
Through chain entanglement, chitosan with a higher MW (longer chain length) can become 
more readily enmeshed with free DNA, once the initial electrostatic interaction has 
occurred. But it will also delay the disassociation of chitosan and DNA (Huang et al., 2005). 
Consequently, low MW chitosan requires a higher charge ratio to stably condense DNA for 
the same DDA, and a lower DDA requires a higher charge ratio to stably condense DNA at 
equal MW (Lavertu et al., 2006). The charge ratio for minimum complexation can be 
determined by agarose gel electrophoresis. 
5. Chitosan structure and physicochemical behaviour 
The structure of chitin and chitosan correspond to those of poly [β(1→4)-2-acetamido-2-
deoxy-d-glucopyranose] and poly[β(1→4)-2-amino-2-deoxy-d-glucopyranose], respectively 
(Figure 1).  Chitosan is mainly manufactured from crustaceans (crab, krill and crayfish) 
primarily because a large amount of the crustacean exoskeleton is available as a byproduct 
of food processing. However, depending on the organism considered chitin can adopt 
polymorphic structures denominated alpha (α), beta (β) and gamma (γ) chitin (Jang et al., 
2004).The polymorphism of chitin is due to different arrangements of chitin chains in the 
lamellas that constitute the crystalline portions. Alpha (α) chitin found in arthropods 
corresponds to an antiparallel chain packing at which intramolecular and intermolecular 
hydrogen bonding is favored. ǃ-Chitin, typically extracted from squid pens, is less widely 
used although it can have higher reactivity than that of α-chitin. The parallel arrangement of 
the lamellas is responsible for a loose-packing fashion with weak intermolecular 
interactions. In the gamma (γ) chitin structure arrangements, beta and alpha occur, i.e., two 
lamellas in a parallel arrangement is intercalated by a lamella arranged in antiparallel 
packing (Roberts, 1992). The source from which chitosan is prepared is considered very 
important since chitosan derived from ǃ-chitin exhibits higher reactivity than that derived 
from ǂ-chitin (Kuritia et al., 1994; Shimojohay 1998).  
In general the isolation of chitin from crustacean shell waste consists of three basic steps: 
demineralization (DM-calcium carbonate and calcium phosphate separation), 
deproteinization (DP-protein separation), and decolorization (DC-removal of pigments). 
These three steps are the standard procedure for chitin production (No et al., 1989). Chitosan 
is obtained after hydrolysis of the acetamide groups of chitin. However in the 
commercialized samples both units are commonly found, since chitosans having high 
deacetylation degrees (DA> 99%) are obtained only through of successive hydrolysis with 
strong bases as KOH and NaOH, and the degree of deacetylation is strongly dependent of 
the alkali concentration and temperature (Figure.1). The source of chitin and the 
deacetylation process can change dramatically the properties of the final product and the 
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deacetylation in alkaline medium leads to the depolimerization (Domard & Rinaudo, 1983; 
Tolaimate et al., 2000). However it has been reported that chitin extracted from squid pens 
can be hydrolyzed under conditions that it allows obtaining chitosans of high molecular 
weight ( Tolaimate et al., 2003). 
 
 
Fig. 1. Chemical structure of chitin and chitosan. In the 2-amino-2-deoxy-d-glucopyranose 
ring is shown the commonly used numbering for the carbon atoms. 
The homopolymer is a weak base with a pKa value of the D-glucosamine residue of about 
6.3 and is therefore insoluble at neutral and alkaline pH values. In acidic mediums, the 
amine groups will be positively charged, conferring to the polysaccharide a high charge 
density. As in all polyelectrolytes, the dissociation constant of chitosan is not constant, but 
depends on the degree of dissociation at which it is determined. The pka value can be 
calculated using the Katchalsky’s equation (Roberts, 1992).  
Pka = pH + log [(1-α)/α] = pK0 –ε∆ψ(α)/kT 
Where ∆ψ is the difference in electrostatic potential between the surface of the polyion 
and the reference, α is the degree of dissociation, k is Boltzman’s constant, T is the 
temperature and ε is the electron charge. Extrapolation of the pKa values to α = 1, where 
the polymer is uncharged and hence the electrostatic potential becomes zero, makes 
possible the value of the intrinsic dissociation constant of the ionizable groups, pK0, to be 
determined. The value obtained does not depend of the degree of N-acetylation, whereas 
the pKa value is dependent on this parameter, since the electrostatic potential will be 
varied depending of amount of the free amino groups. The pK0 value is called the intrinsic 
pKa of the chitosan. However chitosans of low molecular weight having degrees of 
deacetylation higher than 0.4 are also easily soluble in weakly acidic solvents such as 
acetic acid and formic acid (Lee et al., 1995).  
The physicochemical behavior in aqueous solution is highly dependent of pH and degree of 
acetylation and has received more attention only recently. Bertha et al. working on chitosans 
from 95 to 175kDa have recently determined the radius of gyration of chitosan (RG) (Bertha 
et al., 1998a; 2002b). The RG is an alternative measure of the size of the polymer chain and it 
can be measured by light scattering measurements. RG express the square mean radius of 
each one of the elements of the chain measured from its center of gravity. The study 
established the relationship between the molecular weight and radius of gyration (RG) of 
chitosan in aqueous solution, and the author indicated that chitosan behaved more like a 
Gaussian coil instead of the worm-like chain model found in common polyelectrolytes. At 
the same time the presence of N- acetyl groups on the chitosan backbone imparts 
hydrophobic properties. Schatz et al. (Schatz et al., 2003) have studied homogeneous series 
of chitosans with different degrees of acetylation and almost the same degree of 
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polymerization in ammonium acetate buffer. Their results indicate that the aqueous solution 
behavior depends only on the degree of acetylation (DA). Three distinct domains of DA 
were defined and correlated to the different behaviors of chitosans: (i) a polyeletrolyte 
domain for DA below 20%; (ii) a transition domain between DA = 20% and 50% where 
chitosan loses its hydrophilicity; (iii) a hydrophobic domain for DAs over 50% where 
polymer associations can arise. Conformations of chitosan chains varying from 160 to 
270kDa were studied by the calculations of the persistence lengths (L(p)). The average value 
was found to be close to 5 nm, in agreement with the wormlike chain model, but no 
significant variation of L(p) with the degree of acetylation was noticed. Pa et al.  (Pa & Yu, 
2001) have also reported that that the particle sizes of chitosan molecules in dilute acetic 
acid/water solutions increased with decreasing pH value. SLS data also demonstrated that 
the second virial coefficient (A2) increased with decreasing pH value, suggesting that 
solubility of chitosan in water increased with increasing acetic acid concentration. Signini et 
al. (Signini et al., 2000) have also shown that acid-free aqueous solutions of chitosan 
hydrochloride of variable ionic strengths (0:06 M ≤ µ≤ 0.3 M) are free of aggregation as 
evaluated by the values of the Huggins constants (0.31 ≤ k ≤ 0.63). 
As other polysaccharides the biodegradation and biocompatibility are important properties of 
chitosan making it an attractive polymer for a variety of biomedical and pharmaceutical 
applications. Besides the degradation by chitinases (Hung et al., 2002), chitosanases ( Kuroiwa 
et al., 2003), papain (Kumar et al., 2004; Lin et al., 2002; Muzzarelli et al., 2002; Terbojevich et 
al., 1996) and other proteases (Kumar et al., 2004), partially acetylated chitosan may be also 
degraded by lyzosymes of the human serum (Varurn et al., 1997), by oxidative-reductive 
depolymerization (Mao et al., 2004) and by acid hydrolysis reactions (Lee et al., 1999). In the 
acid hydrolysis the protonation of the glycosidic oxygen is recognized as the first step of the 
mechanism, which leads to formation of a cyclic carbonium –oxonium ion, yielding after the 
addition of water the reducing sugar end group (Sinnott et al., 1990; Yip & Withers, 2004). 
Besides enzymatic and acid hydrolysis the alkaline treatment with ultrasonication can be used 
to obtain either chitosan of decreasing molecular weight (Tang et al., 2003)  or oligomers 
having a few glucosamine units (Tsaih et al., 2003). 
6. General strategies for chitosan modification 
In the chitosan structure two groups are particularly susceptible to react through 
nucleophilics attacks, i.e., the free amine and/or acetamide groups, and the hydroxyl groups 
linked to the glucopyranose ring. The hydroxyl groups can be modified by substitution of 
the hydrogen atoms but their reactivities are smaller than that of the amino group. Various 
procedures targeting the hydroxyl groups employ a sequence of protection/deprotection 
reactions aiming to obtain derivatives with a well defined structure (Kuitra, 2001). On the 
other hand under appropriated conditions a variety of other reactions can be easily 
conducted to selectively modify the free amine groups. The literature presents a wide range 
of procedures to target the amine group aiming to improve the properties of chitosan for a 
particular purpose. The modifications include those aiming the separation technologies of 
chiral molecules (Franco et al., 2001), recovery of metals (Guibal, 2004; Varma et al., 2004), 
antimicrobial activity (Rabea et al., 2003), anti tumoral carriers (Kato et al., 2004), biomedical 
applications (Berge et al., 2004a; 2004b) and vectors for gene therapy (Janes et al., 2001; Sinha 
et al., 2004; Liu et al., 2002; Borchard et al., 2001). Kumar et al (Kumar et al., 2004) and Kurita 
(Kurta, 2001) reviewed the procedures for the modification of chitosan.  
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Many strategies have been deployed to improve transfection efficiency, taking into account 
the biological steps involved in gene delivery. Modifications of chitosan structure to impart 
properties to NPs, such as to increase endosomal escape (Jiang et al., 2010; Yu et al., 2010), 
attaching of ligands to mediate cell internalization or to promote the nuclear entry of DNA, 
are among the most common ways. Figure 2 shows representative structures from these 
chitosan derivatives tested as carriers for gene therapy. A variety of nucleophilic reactions 
targeting the groups linked to the glucopyranose ring have been employed to improve the 
properties of chitosan. 
Poly (ethylene glycol) (PEG) has been widely used for attaching to chitosan due to its 
hydrophilicity and biocompatibility. In general, the terminal hydroxyl group of methoxy 
poly(ethylene glycol) is modified to generate PEG derivatives able to promote nucleophilic 
displacements targeting the amino groups of chitosan (Harris et al., 1984; Aiba et al, 1993; 
Saito et al., 1997; Ouchi et al., 1998). Chitosan nanospheres modified by introducing PEG5000 
chains to amine groups were more stable during lyophilization (Leong et al., 1998). These 
chitosan-DNA nanospheres were effective in tranfecting 293 cells but not HeLa cells, and 
tranfection efficiency was not affected by PEG derivatization.  
Polymers can also be attached to the chitosan main chain using different routes. 
Poly(vinyl pyrrolidone) (PVP) was also grafted on galactosylated chitosan (GCPVP) and 
displayed improved physicochemical properties over unmodified chitosan (Park et al., 
2003). PVP with a single terminus carboxylic group was coupled to galactosylated 
chitosan via formation of an amide bond between the amino complex group of GC and the 
terminal carboxyl group of the PVP. The terminal carboxyl group of PVP was activated by 
the N-hydroxysuccinimide (NHS)/EDC. The binding strength of GCPVP 10k/DNA was 
superior to that of GCPVP 50k/DNA, which was attributed to its higher flexibility 
because of its smaller size. However, DNase I protection of GCPVP 10k/DNA complex 
was inferior to that of GCPVP 50k/DNA. The DNA-binding property was shown to be 
dependent on the MW of chitosan and the composition of PVP (Park et al., 2003). The 
reaction of chitosan with methoxy poly(ethylene glycol) iodide (mPEG, Mn 2 kDa) in an 
alkalinized suspension was recently used by Yu et al. to attach PEG (Yu et al., 2010). This 
derivative was subsequently modified by attaching poly(ethylenimine) to the amino 
groups (Figure 2). Other approaches successfully employed to attach PEI to chitosan were 
an imine reaction between periodate-oxidized chitosan and amine groups of low MW PEI 
(Jiang et al., 2007) and the cationic polymerization of aziridine in the presence of water-
soluble oligo-chitosan ( Wong et al., 2006). 
A series of new degradable cationic polymers composed of biocompatible chitosan 
backbones and poly((2-dimethyl amino) ethylmethacrylate) (P(DMAEMA)) side chains were 
recently synthesized via atom transfer radical polymerization (ATR) (Ping et al., 2010). This 
synthesis was carried out by introducing alkyl halide initiators onto chitosan, followed by 
the reaction with DMAEMA. Bromoisobutyryl-terminated chitosan (CS-Br initiators) was 
prepared via the reaction of primary amines of chitosan with carboxyl group of 2-bromo-2-
methylpropionic acid (BMPA), which was previously converted into reactive esters 
(succinimidyl intermediates) in the presence of EDAC and NHS. The reactive esters 
underwent nucleophilic substitution reactions with the amine groups of chitosan to form a 
stable amide linkage and produce the resultant CS-Br initiators for DMAE polymerization 
(Ping et al., 2010). 
The activation of carboxylic groups is one of the most commonly used procedures to attach 
different ligands and peptides to chitosan chain. Arginine-modified trimethylated chitosans 
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labeled with folic acid have been prepared by activation of the acid group of arginine using 
EDC/NHS (Morris et al., 2010). The same procedure was utilized by Gao et al and it has 
proven to increase the transfection efficiency (Gao et al., 2008) and chitosan properties (Liu 
et al., 2004).  A similar procedure was utilized to attach a short peptide (SP) (Sun et al., 2010)   
to chitosan.  The peptide was further combined with GFP/luciferase reporter gene pDNA to 
form SP-CS/DNA complex. The NPs were able to transfect multiple cell lines, and the 
results revealed that, compared with CS, SP-CS could intensively augment transfection 
efficiency nearly to the level of Lipofectamine 2000 (Sun et al., 2010). Reactions targeting the 
hydroxyl groups are uncommon, however Sato et al. have prepared 6-Amino-6-
deoxychitosan from 6-deoxy-6-halo-N-phthaloylchitosan via 6-azidation. The product had 
high stereoregularity because of the effective and regioselective reactions (Saito et al., 2004; 
Satoh et al., 2007).  
 
 
Fig. 2. Chemical structures of chitosan and its derivatives; 1. PEG (Harris et al., 1984); 2. 
trimethylated (Zeng et al., 2007); 3. folic acid (Mansouri et al., 2006; Fernandes et al., 2008); 
4.galactosylated (Park et al., 2001); 5. Arginine (Morris et al., 2010); 6. histidine; 7. PEI and 
PEG grafts (Yu et al., 2010); 8. 6-amino 6-deoxychitosan (Saito et al., 2004; Satoh et al., 2007); 
9. O-hydroethyl  (Kwon et al., 2003); 10. Phosphorylcholine (Case et al., 2009; Tiera et al., 
2006);  11. grafted PDMAEMA (Ping et al., 2010); 12. PEI (Jiang et al., 2007; Wong et al., 
2006).  
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7. Chitosan-DNA delivery system 
Chitosan-DNA gene delivery methods must achieve sufficient efficiency in the 
transportation of therapeutic genes across various extracellular and intracellular barriers. 
These barriers include interactions with blood components, vascular endothelial cells and 
uptake by the reticuloendothelial system. Furthermore, the degradation of therapeutic DNA 
by serum nucleases is a potential obstacle for functional delivery to target cells. DNA should 
escape from endosomes and traffic to enter the nucleus. Many factors, including the degree 
of deacetylation (DDA) and the molecular weight (MW) of the chitosan, the pH of the 
serum, the charge ratio (in some conditions, it equals the ratio of N/P, ‘N’: the content of 
Nitrogen atom in cationic polymer; ‘P’: the content of Phosohorus atom in DNA or RNA) of 
chitosan to DNA or RNA and the cell type can all affect the transfection efficiency of 
chitosan during each step of the process. The pKa value of chitosan is around 6.3-6.4, below 
which the protonated amines in the chitosan structure facilitate their binding to negatively 
charged DNA. Sato et al. showed the highest transfection efficiency can be obtained at pH 
6.8 to 7.0. When pH of the transfection medium increases to 7.4, the transfection efficiency 
dramatically decreases due to the dissociation of the free plasmid from the complex (Sato et 
al., 2001). 
Even if chitosan/DNA complexes display high transfection efficiency in vitro, their 
transfection efficiency in vivo may be low. Chitosan and its derivatives have become of great 
interest in the field of controlled release due to their favorable biocompatibility and 
biodegradability. Thiolated chitosan, which can be oxidized to form inter- and intra- 
molecular disulfide bonds, allowing the crosslinking of chitosan, shows a significant 
enhancement of transfection over that of lipofectin (Lee et al., 2007). Chitosan microspheres 
for micro-encapsulation of adenoviral vectors has been achieved by ionotropic coacervation 
of chitosan, using bile salts as counter-anions (Lameiro et al., 2006). A 3-D scaffold 
composed of chitosan-gelatin complexes with entrapped DNA has been proposed as a 
promoter of cartilage regeneration (Xia et al., 2004).   
Although hydrophobic modification is not cell-specific, it can also enhance the attachment of 
complexes on cell surfaces and the subsequent cell uptake. Amphiphobic deoxycholic acid-
modified chitosan oligosaccharide (DACO) nanoparticles showed superior gene 
condensation and high gene transfection efficiency, even in the presence of serum (Chae et 
al., 2005). After endocytosis, the endosome containing the complexes has to fuse with a 
lysosome to form an endolysosome. At this point, the complexes will meet a harsh acidic 
and multienzymatic environment. Nanocomplexes that are successfully protected against 
dissociation and degradation will finally escape from the endolysosome and enter the 
cytoplasm. PEI, a classic synthetic polymer with many amino groups to absorb protons 
(called a proton sponge mechanism), was found to have a better endolysosome buffering 
ability and caused a quicker release from the endolysosome in its intact form than did 
chitosan (Kim et al., 2005). The chemical modifications, such as urocanic acid (UA) (Kim et 
al., 2003), PEI-graft-chitosan (Wong et al., 2006), chitosan-graft-PEI (Jiang et al., 2007), 
poly(propyl acrylic acid) (PPAA) (Jones et al., 2003), trimethyl chitosan (Germershaus et al., 
2008), have similar effects to PEI. Such modifications can be called pH-sensitive 
modifications that will not only enhance the escape of chitosan/DNA complexes from 
endolysosome but also enhance the stability of complexes in different pH situations. 
The dissociation of chitosan/DNA complexes and subsequent release of DNA is also a very 
important step for its rate-limiting effect (Schaffer et al., 2000). Hydrophobic modification, 
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such as deoxycholic acid modification (Lee et al., 1998), or 5β-cholanic acid modification 
(Yoo et al., 2005), can attenuate the electrostatic attractions between cationic polymers and 
anionic DNA. It is actually a contradiction between the stability and dissociation ability of 
complexes. A temperature-sensitive modification of poly(N-isopropylacrylamide) 
(PNIPAAm) can control the dissociation of PNVLCS (N-isopropylacrylamide/vinyl laurate 
copolymer with chitosan) complexes with DNA by a temporary reduction in the culture 
temperature to 20℃ (Sun et al., 2005) 
The cytoplasm, a mesh-like network of microfilaments and microtubules, will limit the 
diffusion of complexes or DNA about 500-1000-fold. Adenovirus particles naturally bind to 
dynein and are actively transported towards the nuclear pore complexes once they are 
inside the cytoplasm. Prior to entry into the nucleus, the viruses dissociate into smaller 
structures and use their attached transport factors such as importins or karyopherins which 
have nuclear localization signals (NLS) to recognize the nuclear pore complex (NPC) 
(Whittaker & Helenius, 1998). Justin Hanes et al. used a new method called multiple 
particles tracking (MPT) to quantify the intracellular transport of non-viral DNA 
nanocarriers. They found that PEI/DNA complexes can accumulate in the perinuclear area 
through a subdiffusive transport, which is a combination of diffusive transport and active 
transport. This discovery is a dispute to the common belief that non-viral vectors go through 
the cell cytoplasm in a slow random way. Further investigation showed that actively 
transported complexes of PEI/DNA are in endosomes undergoing motor protein-driven 
movement guided by microtubules or physically associated with the motor proteins 
themselves (Suh et al., 2003). As to chitosan and its derivatives, however, few studies have 
examined how they pass through the highly structured cytoplasm and eventually enter into 
the nucleus. 
8. Chitosan-siRNA delivery system 
siRNA silencing technology is exploited in a wide range of biological studies, but has also 
become one of the most challenging therapeutic strategies. However, because of its poor 
delivery and susceptibility to nuclease degradation, siRNA-based approaches need a 
protective delivery system. A variety of polymer formulations have been proposed in the 
literature as potential carriers (De Fougerolles 2008; Gary et al., 2007; Zhang et al., 2007). 
Polymer molecular weight, change density, N/P ratio (ratio of protonatable polymer amine 
groups to nucleic acid phosphate groups) and ionic strength of the medium can affect 
electrostatic binding between siRNA and cationic polymers. Research over the years has 
revealed that chitosan is one of the desirable polymeric carriers of siRNA because of its 
natural biocompatibility, biodegradability, nontoxicity, and high nuclease resistance. The 
effects of different chitosan (114-kDa or more)-siRNA complexes on transfection activity 
have been observed previously (Katas et al., 2008; Katas & Alpar, 2006; Liu et al., 2007; 
Rojanarata et al., 2008). Higher MW and DDA are desirable characteristics for the formation 
of chitosan nanoparticles, as higher MW chitosan molecules are long and flexible while 
higher DDA enhances its electrostatic interaction with siRNAs, thus synergically reducing 
the size of complexes and increasing their stability (Liu et al., 2007). A high charge ratio also 
enhances the stability of complexes because the loosely bound excess chitosan on the outer 
surface of nanoparticles can promote binding and uptake across anionic cell surfaces and 
also provide subsequent protection against siRNA degradation within endosome 
compartments  (Liu et al., 2007). The method of complexation also affects the gene-silencing 
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activity of chitosan/siRNA complexes. Haliza Katas et al. studied the difference between 
simple complexation, ionic gelation (siRNA entrapment) and adsorption of siRNA onto the 
surface of preformed chitosan nanoparticles. Ionic gelation gave the strongest stability and 
the most efficient gene-silencing activity among the three methods tested. For the 
involvement of tripolyphosphate (TPP) ions during the complexation of ionic gelation, pH 
became one of the factors that mostly affected the gene-silencing activity. The decrease of 
pH resulted in a reduction in the charge number of TPP, which subsequently led to the need 
for more TPP ions for cross-linking of the chitosan by electrostatic forces (Katas & Alpar, 
2006). Rojanarata et al. reported that chitosan-thiamine pyrophosphate (TPP)-mediated 
siRNA enhanced green fluorescent protein (EGFP) gene silencing efficiency depended on 
the molecular weight and weight ratio of chitosan and siRNA. The chitosan-TPP-siRNA 
complex with the lowest molecular weight of chitosan (20 kDa) at a weight ratio of 80 
showed the strongest inhibition of gene expression (Rojanarata et al., 2008). A novel study of 
chitosan/siRNA nanoparticles with fluorescent quantum dots was taken to silence 
HER2/neu and achieved desirable silencing effects (Tahara et al., 2008; Tan et al., 2007). In 
the field of controlled release, chitosan coating PLGA nanospheres with a high loading 
efficiency of siRNAs were found to reduce the initial burst of nucleic acid release and to 
prolong release at later stages, without changing the release pattern (Tahara et al., 2008). 
Kenneth A. Howard found that the chitosan-based system had the ability for endosome 
escape through the proton sponge mechanism, because the endosomolytic agent 
chloroquine did not increase the effect of RNA interference (Howard et al., 2006). In terms of 
in vivo administration of chitosan/siRNAs complexes, only a few studies are available. 
Nasal administration to silence EGFP expression of the endothelial cells distributed in the 
bronchioles of transgenic EGFP mouse model has been successfully achieved without 
showing any adverse effects (Howard et al., 2006). Cross-linking of hyaluronan and chitosan 
has proven to have a higher efficiency of transfection in ocular tissue over unmodified 
chitosan (de la Fuente et al., 2008). 
9. Potential application of chitosan-DNA/siRNA nanoparticles 
Gene therapy offers new possibilities for the clinical management of different disease 
conditions that are difficult to treat by traditional surgical or medical means. In the last 
decade, extensive improvements have been made to optimize gene therapy and have been 
tested on several disease conditions. The success of chitosan-DNA nanoparticles for delivery 
plasmid DNA to mucosal surfaces such as the oral and nasal mucosa has already shown 
(Bivas-Benita et al., 2003; Chen et al., 2004; Khatri et al., 2008). Oral delivery is most 
attractive due to easy administration. The oral delivery of peptide, protein, vaccine and 
nucleic acid-based biotechnology products is the greatest challenge facing the drug delivery 
industry. Mice were fed with plasmid pCMVβ (containing LacZ gene), whether it was 
wrapped by chitosan or no. The study demonstrated that oral chitosan-DNA nanoparticles 
can efficiently deliver genes to enterocytes, and may be used as a useful tool for gene 
transfer (Chen et al., 2004). Hepatitis B virus infection is a major global health concern and is 
the most common cause of chronic liver disease, new generation of HBV vaccines are 
urgently needed in order to overcome problems encountered with the immunization of 
immunocompromised people and more importantly with the potential of using active 
immunotherapy in treating chronic patients. DNA vaccines have the potential to eliminate 
many of the limitations of current vaccine technologies. Chitosan nanoparticles loaded with 
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plasmid DNA encoding surface protein of Hepatitis B virus. Nasal administration of such 
nanoparticles resulted in serum anti-HBsAg titre that was less compared to that elicited by 
naked DNA and alum adsorbed HBsAg, but the mice were seroprotective within 2 weeks 
and the immunoglobulin level was above the clinically protective level (Khatri et al., 2008). 
Particulate mucosal delivery systems that encapsulate protein or plasmid DNA encoding 
antigens have been widely explored for their ability to induce an immune response. Oral 
delivery of vaccines using chitosan as a carrier material appears to be beneficial for inducing 
an immune response against Toxoplasma gondii.  Chitosan microparticles as carriers for GRA-
1 protein vaccine were prepared. It was shown that priming with secreted dense granule 
protein 1 (GRA1) protein vaccine loaded chitosan particles and boosting with GRA1 pDNA 
vaccine resulted in high anti-GRA1 antibodies, characterized by a mixed IgG2a/IgG1 ratio 
(Bivas-Benita et al., 2003). The application of chitosan-based delivery system as ocular gene 
carriers, there is evidence of their ability to transfect the ocular cells in vitro. This capacity of 
chitosan nanoparticles to transfect the cells, was found to be highly dependent on the 
molecular weight of chitosan. Only chitosan of low molecular weight (10-12 kDa) was able 
to transfect plasmid DNA in both cell lines derived from the human cornea and the 
conjunctives (De la Fuente et al., 2008). In Utero delivery of chitosan-DNA results in 
postnatal gene expression, and shows promise for non-viral gene transfer in animal models 
of fetal gene therapy (Yang et al., 2010). The intravenous and intratracheal solutions and the 
intratracheal powder of pCMV-Muǃ encoding murine interferon-ǃ were administered the 
day after the inoculation of mice with CT26 cells. Lung weight and the number of 
pulmonary nodules at day 21 were significantly suppressed by the three formulations at a 
dose of 10 μg (N/P = 5). Reducing the dose to 1 μg resulted in a loss of effect by the 
intravenous solution (Okamoto et al., 2010). These findings showed that therapeutic gene 
powders are promising for gene therapy to treat lung cancer or metastasis. 
siRNA gene therapy research has focused on several types of viral vectors: adeno-associated 
viruses (AAV), adenoviruses, retroviruses, lentiviruses, and herpes simplex viruses. siRNA 
therapeutics have been assessed in numerous diseases, including genetic and viral diseases, 
cancer, as well as non-lethal disorders, such as arthritis and osteoporosis. Among these viral 
vectors, lentiviruses have progressed to clinical trials on metastatic melanoma and HIV 
infection (Baker, 2010a; 2010b). siRNA-based gene therapy has already been tested in clinical 
trials dealing with the treatment of age-related macular degeneration, viral infection, skin 
disorders and cancer.  Cancer treatment is by the most important proposed application of 
gene therapy and many clinical trials using gene therapy are under investigation. Non-viral 
vectors including chitosan derivatives have been used in animal model, but clinical trials are 
lagging due to low transfection efficiency. Anderson et al. (Andersen et al., 2008) 
demonstrated that silencing of pro-inflammatory TNFα in the RAW 246.7 murine 
macrophage cell line was achieved by using lyophilized chitosan/siRNA. Compared to 
research in vitro with chitosan-based systems, in vivo research is still in the developmental 
stage. Only a few studies are avaible which in vivo demonstration of chitosan/siRNA 
nanocomplexes in silencing gene expression in animals. Howard et al. (Howard et al., 2009) 
demonstrated that chitosan nanopaticles contains an anti-TNFα siRNA knock downed 
efficiently of TNFα expression in primary peritoneal macrophages in vitro. Downregulation 
of TNFα-induced inflammatory responses arrested systemic and local inflammation in 
collagen-induced arthritic mice after intraperitoneal injection of chitosan/anti-TNFα siRNA 
nanoparticles, thereby presenting a novel strategy for arthritis treatment. 
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10. Conclusion 
Clinical trials on gene therapy are limited to naked DNA or plasmid DNAs/siRNA 
delivered by viral vectors. Among non-viral vectors for DNA and siRNA delivery, chitosan 
and its derivatives are promising alternatives to viral vectors for targeting DNA and siRNA 
to specific cells. Chitosan has once been considered as an attractive gene transfer candidate 
for its superior biocompatibility, superior biodegradability and low cell toxicity, but the low 
stability, low buffering capacity and low cell-specificity have also hindered its clinical 
applications. To date, however, no clinical trials of chitosan-DNA or siRNA therapy have 
been performed. Chitosan-based gene therapy remains in the experimental stage due to low 
transfection efficacy. Many key challenges were involved in DNA and siRNA delivery to 
targeted cells using chitosan-based carriers. As a nature resource-based polysaccharide, 
chitosan has more functional groups that can be chemically modified than do the other 
cationic polymers, thus has many more potential chemical derivatives to make up these 
deficiencies. Parameters are critical to achieve favourable transfection efficiency and include 
degree of deacetylation, molecular weight, pH and N/P ratio. For example, a low molecular 
weight, high degree of deacetylation, small particle size and a moderate, positive, surface 
zeta potential along with a high N/P ration are advantageous to achieve high siRNA 
transfection efficiency. Recent technological advances in the chemical modification of 
chitosan have instituted improvements of its transfection efficiency without disturbing its 
biocompatibility and biodegradability.  
Our work on gene coding for IL-lRa in dogs (Pelletier et al., 1997) and rabbits (Fernandes et 
al., 1999) was our previous study with the protein itself. We have improved a non-viral 
intraarticular transfection technique using lipofection and have tested it in osteoarhtritis 
animal models. These were the very first published articles in the literature that 
demonstrated the efficacy of gene therapy in osteoarthritis models in vivo. Our recent work 
on polymeric nanoparticles has led us to develop a much safer and effective system for in 
vitro transfection of embryonic kidney cells, as well as adult mesenchymal stem cells  (Corsi 
et al., 2003). This new system has been successfully tested in muscle and skin tissues in vivo 
in mice and holds great promise for future application on the field of gene therapy and 
tissue engineering. We developed a second-generation nanovector by successfully coupling 
folic acid to the polymer (Mansouri et al., 2006). One strategy for improving transfection is 
to take advantage of the mechanism of folate-mediated uptake by cells to promote targeting 
and internalization, hence improving transfection efficiency. Folate-mediated transfection 
has been shown to facilitate DNA internalization into cells via membrane receptors both in 
vitro and in vivo (Sudimack & Lee, 2000). Expression of folate receptor (FR)-β in synovial 
mononuclear cells and CD14+ cells from patients with RA was described by 1999 
(Nakashima-Matsushita et al., 1999). Articular macrophages isolated from rats with 
adjuvant-induced arthritis overexpress FRs and exhibit significantly higher binding capacity 
for folate conjugates than macrophages obtained from healthy rats (Turk et al., 2002). The 
wide distribution of FRs at the surface of activated macrophages in rheumatoid arthritis 
allows the use of folate as potential ligand for folate-targeted chitosan gene therapy. Our 
laboratory demonstrated that folate-chitosan DNA nanoparticle containing IL-1Ra has been 
shown to play a role to prevent abnormal osteoblast metabolism and bone damage in this 
adjuvant-induced arthritis model (Fernandes et al., 2008). It also allows a significant 
decrease of the inflammation in the rats’ paw compared to untreated rats, proving indirectly 
the efficacy of the IL-1Ra protein treatment. Various inflammation markers (IL-1ǃ and PGE2) 
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showed a significant decrease in muscle and serum after the injection of the IL-1Ra protein 
demonstrating by direct evidence the efficacy of the administration technique to deliver 
efficient nanoparticles. Therefore, we have already shown it is possible to do gene therapy 
with IL-1Ra to decrease arthritis and have a positive effect on inflammation.  
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